Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Eplerenone Coated Tablets in Healthy Subjects
NCT02957435Phase 1Withdrawn
- Sponsor
- Biolab Farmacêutica
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eplerenone in hypertension (HTN) and heart failure (HF), sponsored by Biolab Farmacêutica. Primary endpoints: Maximum serum concentration at 24 hours and Area under the curve (ASCo-t) at 24 hours. Planned start Jul 2017; status: withdrawn.
02
Drugs
eplerenone
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT02957435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957435.